Sign in

Private company

Lucy Scientific Discovery, Inc.

Lucy Scientific Discovery, Inc. is a Canadian pharmaceutical preparations company, incorporated in British Columbia.1 It is headquartered in Victoria, Canada.1

Last updated Oct 21, 2026.

Overview

$7.0KRevenue, fiscal 20232
-$9.0MNet income, fiscal 20232
  • IndustryPharmaceutical Preparations1
  • HeadquartersVictoria, Canada1
  • Incorporated inBritish Columbia, Canada3
  • Business address301-1321 Blanshard Street, Victoria, A1 V8W 0B63
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

36.2%Gross margin2
-82919.7%Operating margin2
-127532.0%Net margin2
-192.1%Return on equity2
0.00×Debt to equity2

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue0¢$4.5K
  • Selling, general and admin75¢$5.8M
  • Interest25¢$2.0M

Out of $7.0K in revenue.2 The company lost money this year.

Financial statements

Operating income2-$5.8M in 2023+68% since 2022
-$6.0M-$4.0M-$2.0M02022: -$3.5M-$3.5M20222023: -$5.8M-$5.8M2023+68%
Net income2-$9.0M in 2023+53% since 2022
-$10.0M-$7.5M-$5.0M-$2.5M02022: -$5.9M-$5.9M20222023: -$9.0M-$9.0M2023+53%
Fiscal year202120222023
Revenue$7.0K2
Cost of revenue$4.5K2
Gross profit$2.5K2
Selling, general and admin$3.5M2$5.8M2
Operating expenses$3.5M2$5.8M2
Operating income-$3.5M2-$5.8M2
Interest$2.1M2$2.0M2
Net income-$5.9M2-$9.0M2
Earnings per share-$0.682-$0.712
Earnings per share (diluted)-$0.682-$0.712
Shares (weighted, basic)8.6M shares212.7M shares2
Shares (weighted, diluted)8.6M shares212.7M shares2

Compare Lucy Scientific Discovery, Inc. with another company

Corporate structure

Lucy Scientific Discovery, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Lucy Scientific Discovery, Inc.

  • AdvisorShares Trust Filed SCHEDULE 13G/A on Lucy Scientific Discovery, Inc., latest Apr 2, 2025 (2 filings since Nov 12, 2024)
  • Lucy Scientific Discovery, Inc. Victoria, Canada

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lucy Scientific Discovery, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$764.6K2 Jun 30, 2023$843.5K2 Jun 30, 2022−9.3%
Property and equipment, net$764.6K2 Jun 30, 2023$843.5K2 Jun 30, 2022−9.3%
Operating-lease assets (leased space)$1.0M2 Jun 30, 2023

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.7M2 Jun 30, 2023$53.4K2 Jun 30, 2022+3035.8%
Long-term investments$18.9K2 Jun 30, 2023$19.4K2 Jun 30, 2022−2.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.5M2 Jun 30, 2023
Finite-lived intangibles, net$1.5M2 Jun 30, 2023

Leadership

Who has led Lucy Scientific Discovery, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christopher McElvany2023

Chair

  1. Richard D. Nanula2023

President

  1. Christopher McElvany2023

Chief financial officer

  1. Brian Zasitko2023
2025
Board members and other officers (5)

Timeline

  1. Jul 1, 20248-K Listing notice or transfer13
  2. May 28, 20248-K Listing notice or transfer14
  3. May 9, 20248-K Listing notice or transfer; Executive or director change15
  4. Apr 23, 20248-K Executive or director change16
  5. Mar 12, 20248-K Ended a material agreement17
  6. Feb 27, 20248-K Other events18
  7. Feb 23, 20248-K Listing notice or transfer19
  8. Dec 18, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares20
  9. Sep 27, 20238-K Listing notice or transfer21
  10. Sep 12, 20238-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure22
  11. Sep 8, 20238-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure23
  12. Jul 28, 20238-K Executive or director change24
  13. Feb 9, 2023New chief executive Christopher McElvany becomes CEO6

Filings

87 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 17 major events, 12 insider forms, 2 large holders, 51 other. The latest 20:

  1. Apr 3, 2025144 EDGAR
  2. Apr 3, 2025144 EDGAR
  3. Apr 3, 2025144 EDGAR
  4. Apr 3, 2025144 EDGAR
  5. Apr 3, 2025144 EDGAR
  6. Apr 2, 2025SCHEDULE 13G/A EDGAR
  7. Nov 12, 2024SC 13G EDGAR
  8. Jul 1, 20248-K CURRENT REPORT EDGAR
  9. May 28, 20248-K CURRENT REPORT EDGAR
  10. May 15, 2024NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  11. May 9, 20248-K CURRENT REPORT EDGAR
  12. Apr 23, 20248-K CURRENT REPORT EDGAR
  13. Mar 12, 20248-K CURRENT REPORT EDGAR
  14. Mar 1, 2024424B3 PROSPECTUS EDGAR
  15. Feb 27, 2024EFFECT EDGAR
  16. Feb 27, 20248-K CURRENT REPORT EDGAR
  17. Feb 26, 2024CORRESP EDGAR
  18. Feb 23, 20248-K CURRENT REPORT EDGAR
  19. Feb 22, 2024S-1/A REGISTRATION STATEMENT EDGAR
  20. Feb 13, 202410-Q QUARTERLY REPORT EDGAR

The 87 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Lucy Scientific Discovery, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLucy Scientific Discovery, Inc.1
  • CIK0001865127
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inBritish Columbia, Canada1
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address301-1321 Blanshard Street, Victoria, A1 V8W 0B61
  • Phone778-410-51951
  • Shares outstanding17,646,296 as of Feb 13, 20244
  • Public float$0 as of Dec 31, 20222
  • On EDGAR sinceSep 28, 20211
  • Filings89 in all: 8-K (16), CORRESP (16), S-1/A (11), 3 (9), 144 (5), 10-Q (4), FWP (4), 4 (3)1
    All 24 form types

    UPLOAD (3), 425 (2), EFFECT (2), S-1 (2), 10-K (1), 25-NSE (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), NT 10-K (1), NT 10-Q (1), SC 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Oct 13, 2023
    Quarterly report (10-Q) Feb 13, 2024
    Latest 8-K (8-K) Jul 1, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    SEC EDGAROther events
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25